Krystal Biotech, Inc. SEC filings KRYS
Krystal Biotech, Inc. has 513 filings in SEC EDGAR's recent list, going back to Jul 14, 2017. Its latest annual report, Form ARS, was filed on Apr 3, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 2, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 2, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 3, 2026 | — |
| DEF 14A | Proxy statement | Apr 3, 2026 | Apr 3, 2026 |
| DEFA14A | Additional proxy material | Apr 3, 2025 | — |
| DEF 14A | Proxy statement | Apr 3, 2025 | Apr 3, 2025 |
| DEFA14A | Additional proxy material | Apr 4, 2024 | — |
| DEF 14A | Proxy statement | Apr 4, 2024 | Apr 4, 2024 |
| DEFA14A | Additional proxy material | Apr 4, 2023 | — |
| DEF 14A | Proxy statement | Apr 4, 2023 | — |
| DEFA14A | Additional proxy material | Apr 7, 2022 | — |
| DEF 14A | Proxy statement | Apr 7, 2022 | May 20, 2022 |
| DEFA14A | Additional proxy material | Apr 6, 2021 | — |
| DEF 14A | Proxy statement | Apr 6, 2021 | May 21, 2021 |
| DEFA14A | Additional proxy material | May 8, 2020 | — |
| DEF 14A | Proxy statement | Apr 13, 2020 | May 29, 2020 |
| DEFA14A | Additional proxy material | Apr 15, 2019 | — |
| DEF 14A | Proxy statement | Apr 15, 2019 | May 30, 2019 |
| DEF 14A | Proxy statement | Apr 20, 2018 | May 31, 2018 |
Showing 17 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- KRYS (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Pittsburgh, PA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1711279
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.